Because surgery and ablation can not completely remove cancer cells in patients, and liver cancer is not sensitive to traditional radiotherapy and chemotherapy, it is always a medical problem for patients to relapse and metastasis after local treatment such as ablation. According to statistics, after 5 years of local treatment, the recurrence rate of liver cancer is as high as 60-70%. In recent 10 years, tumor immunotherapy has become a promising treatment method because of its advantages in delaying tumor progression and protecting patients'anti-tumor immune function. Ralph Steinman won the Nobel Prize in Physiology or Medicine on October 3, 2011 for "the first discovery of dendritic cells in the immune system and their unique activation and regulation in acquired immunity"; on December 20, 2013, "Cancer Immunotherapy" was listed as the year of Science. The first breakthrough in science. On October 1, 2018, two immunologists, James Allison of the United States and Yasumoto of Japan, won the Nobel Prize in Physiology or Medicine for their contribution to the discovery of negative immunomodulation therapy for cancer. Cellular immunotherapy can eliminate the immunosuppressive state caused by tumors, activate the immune system of the body directly killing the immune cells of tumor cells, and completely remove the small lesions and residual tumor cells in the body of cancer patients. The treatment method is safe and effective. In 2009, autologous cell immunotherapy technology was listed in the first category III medical technology catalogue which was released by the Ministry of Health to allow clinical application.